14 May 2014 - On Tuesday, May 13, Vertex met in Toronto with the Health Ministers from Alberta and the Yukon as part of our ongoing discussions regarding the public reimbursement of ivacaftor (Kalydeco) in Canada.

“While we had a lengthy discussion, we have not yet reached an agreement with the provincial and territorial governments, despite the fact that our proposal is as good as or better than the agreements in place in 15 countries around the world where people with CF are receiving the medicine through public reimbursement,” said Stuart Arbuckle, Executive Vice President and Chief Commercial Officer for Vertex. “We are extremely disappointed that today’s meeting did not result in an agreement to allow the eligible children and adults with CF in Canada to receive this medicine through public reimbursement. People with CF are still waiting for access to Kalydeco, and this process is taking much longer than they expect and deserve.”

Based on the meeting, both parties have committed to further discussions this week.

For more details, go to: http://www.vrtx.com/assets/pdfs/CorporateStatementCanada.pdf